Abstract
The increasing prevalence of obesity world-wide has an expected consequent increase in diabetes and cardiovascular disease. Less attention has been paid to the effect of obesity on dementia. This overview discusses methodological issues related to the epidemiologic study of obesity and dementia, reviews results of long-term prospective studies, and briefly considers possible mechanisms for an obesity-dementia association. At least six cohort studies of 18 to 32 years duration confirm that overweight middle-aged or older adults are at increased risk of dementia in later life. In many of these studies, the association persisted after adjusting for classical cardiovascular risk factors. A few epidemiologic studies (and more laboratory studies not reviewed here) suggest biomarkers such as C-reactive protein, interleukin 6, and leptin may explain part of the obesity-dementia connection. If any of these factors are in the causal pathway to dementia, their reversal or prevention by weight control would have huge public health importance.
Keywords: Obesity, dementia, biomarkers, prevention, prospective studies
Current Alzheimer Research
Title: An Introduction to Obesity and Dementia
Volume: 4 Issue: 2
Author(s): Elizabeth Barrett-Connor
Affiliation:
Keywords: Obesity, dementia, biomarkers, prevention, prospective studies
Abstract: The increasing prevalence of obesity world-wide has an expected consequent increase in diabetes and cardiovascular disease. Less attention has been paid to the effect of obesity on dementia. This overview discusses methodological issues related to the epidemiologic study of obesity and dementia, reviews results of long-term prospective studies, and briefly considers possible mechanisms for an obesity-dementia association. At least six cohort studies of 18 to 32 years duration confirm that overweight middle-aged or older adults are at increased risk of dementia in later life. In many of these studies, the association persisted after adjusting for classical cardiovascular risk factors. A few epidemiologic studies (and more laboratory studies not reviewed here) suggest biomarkers such as C-reactive protein, interleukin 6, and leptin may explain part of the obesity-dementia connection. If any of these factors are in the causal pathway to dementia, their reversal or prevention by weight control would have huge public health importance.
Export Options
About this article
Cite this article as:
Barrett-Connor Elizabeth, An Introduction to Obesity and Dementia, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362074
DOI https://dx.doi.org/10.2174/156720507780362074 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Fragile X Families: A Lifespan Perspective)
Current Psychiatry Reviews Experience and Perspectives of Caregivers of Spouse with Mild Cognitive Impairment
Current Alzheimer Research Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer’s Disease Patients and Age-matched Controls
Current Alzheimer Research Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment
Current Medicinal Chemistry Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment
Current Drug Abuse Reviews Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Editorial [Hot topic: Fixing Alzheimer Disease Trials by Improving Process and Methods (Lon S. Schneider)]
Current Alzheimer Research Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer’s Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience
Current Pharmaceutical Design Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets